Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Jefferam1on Feb 01, 2017 9:47pm
171 Views
Post# 25786961

RE:Heading towards October...

RE:Heading towards October...I think the fate will lie in July.
Everything is contingent on favorable results from the clincial trial. Sure there might be a slight increase with some swings leading up to it. I'm sure we will hit the 30 cent range, not so sure if we will have enough legs to hit 40. But once we have a results in July it will be hit or bust.
One thing I will bet on is volatility. I confident this stock will not be trading 0.15-0.30 after the news release in July. And I think that is the reason why we are not higher today. Even though the toxicity issue is more understood people are still scared of loosing all. Too much risk for investors. They are all waiting for these results first. If favorable, the large funds may start to pickup and price could jump by 50 cents in a matter of hours or days.
Then comes some deal at the end of year and we can be in the $1-$2 range.
That's my hopes anyway.
Yes I have nothing to concrete to base any of the above on. Going mostly on dumb gut luck.
But I say dream big! I just hope I'm not going for broke.
 
Bullboard Posts